RT Journal Article
T1 The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii.
A1 Amat, T
A1 Gutierrez-Pizarraya, A
A1 Machuca, I
A1 Gracia-Ahufinger, I
A1 Perez-Nadales, E
A1 Torre-Gimenez, A
A1 Garnacho-Montero, J
A1 Cisneros, J M
A1 Torre-Cisneros, J
K1 Acinetobacter baumannii
K1 Bacteriemia
K1 Carbapenem-resistant
K1 Colistin
K1 Tigecycline
AB To assess the association of survival and treatment with colistin and tigecycline in critically ill patients with carbapenem-resistant Acinetobacter baumannii bacteraemia. An observational cohort study was carried out. Targeted therapy consisted of monotherapy with colistin (9 million UI/day) or combined therapy with colistin and tigecycline (100 g/day). The primary outcome was 30-day crude mortality. The association between combined targeted therapy and mortality was controlled for empirical therapy with colistin, propensity score of combined therapy and other potential confounding variables in a multivariate Cox regression analysis. A total of 118 cases were analysed. Seventy-six patients (64%) received monotherapy and 42 patients (36%) received combined therapy. The source of bacteraemia was primary in 18% (21/118) of the patients, ventilator-associated pneumonia in 64% (76/118) and other sources in 14% (16/118). The 30-day crude mortality rate was 62% (42/76) for monotherapy and 57% (24/42) for combined therapy. The variables associated with 30-day crude mortality were: Charlson index (hazard ratio (HR) 1.16, 95% CI 1.02-1.32; p 0.028), empirical therapy with colistin (HR 2.25, 95% CI 1.33-3.80; p 0.003) and renal dysfunction before treatment (HR 1.91, 95% CI 1.01-3.61; p 0.045). Combined targeted therapy was not associated with lower adjusted 30-day crude mortality (adjusted HR 1.29, 95% CI 0.64-2.58; p 0.494). Combined targeted therapy with high-dose colistin and standard dose tigecycline was not associated with lower crude mortality of bacteraemia due to carbapenem-resistant A. baumannii in critically ill patients. 
PB Elsevier
YR 2017
FD 2017-09-21
LK http://hdl.handle.net/10668/11638
UL http://hdl.handle.net/10668/11638
LA en
NO Amat T, Gutiérrez-Pizarraya A, Machuca I, Gracia-Ahufinger I, Pérez-Nadales E, Torre-Giménez Á, et al. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii. Clin Microbiol Infect. 2018 Jun;24(6):630-634
NO Supported by Planes Nacionales de IþDþi 2008e2011/2013e2016 and Instituto de Salud Carlos III, Subdireccion General de Redes y Centros de Investigacion Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015/0001, RD12/0015/0002 and REIPI RD16/0016/0008, REIPI RD16/0016/0009) co-financed by European Development Regional Fund A way to achieve Europe and operative programme Intelligent Growth 2014e2020.
DS RISalud
RD Apr 18, 2025